Skip to content
2000
Volume 12, Issue 3
  • ISSN: 1574-8847
  • E-ISSN: 2212-3938

Abstract

Background: The prevalence of anticoagulant use has increased in the United States. Medical providers have the responsibility to explain to patients the management of anticoagulant regimens before an invasive procedure. The pharmacologic characteristics of these medications, specifically their half-lives, are important in timing an interruption of anticoagulant therapy. Objective: The authors review the current guidelines and recommendations for therapeutic interruption of anticoagulants and the involved pharmacologic factors. Methods: Guidelines and other literature are summarized with discussion on the pharmacology of each medication. Recommendations on how and when to provide bridging for anticoagulants are discussed. Newer oral anticoagulants also are discussed, along with interruption recommendations. Results: Literature reveals a conservative approach for using bridging when anticoagulation is interrupted because of higher risks of bleeding. Caution is advised when resuming anticoagulant therapy when neuraxial anesthesia is used. Conclusion: Perioperative healthcare providers need to balance risks and benefits of anticoagulant therapy with its interruption preoperatively.

Loading

Article metrics loading...

/content/journals/ccp/10.2174/1574884712666170822092709
2017-08-01
2025-05-25
Loading full text...

Full text loading...

/content/journals/ccp/10.2174/1574884712666170822092709
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test